In clinical studies to date, SBP-101 has not shown exacerbation of the typical chemotherapy-related adverse events of bone marrow suppression and peripheral neuropathy. The molecule has shown signals of tumor growth inhibition in clinical studies of US and Australian metastatic pancreatic cancer patients, suggesting complementary activity with an existing FDA-approved chemotherapy regimen. SBP-101 is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for the exocrine pancreas and pancreatic ductal adenocarcinoma. The call will also be available over the Internet and accessible at: To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.Ī replay of the call will be available from Novemthrough November 26, 2020 Total current assets were $11.4 million and current liabilities were $1.9 million as of the same date. Total cash was $10.9 million as of September 30, 2020. Net loss in the third quarter of 2020 was $1.7 million, or $0.21 per diluted share, compared to a net loss of $1.4 million, or $0.23 per diluted share, in the third quarter of 2019. The change in the third quarter is due primarily to increased employee compensation expense. General and administrative expenses increased to $1.2 million in the third quarter of 2020, up from $0.6 million in the third quarter of 2019. Third Quarter ended SeptemFinancial Results Initiation of randomized phase 2 study (1H'21) We believe SBP-101 has the potential to expand into other cancers with known elevated levels of polyamine metabolism.Ĭompletion of enrollment in the expansion cohort targeting (Q4'20)Ĭonference presentations (1H'21 or 2H'21) Looking ahead, we’re focused on rapidly advancing SBP-101’s clinical development to create significant shareholder value.”īased on interim data from our Phase I trial, SBP-101 demonstrated a 54% objective response rate in combination with gemcitabine & abraxane (G&A) more than double historical standard of care for metastatic pancreatic cancer with G&A. Those upcoming milestones include completing SBP-101’s enrollment in the current Phase 1b trial in Q4 2020, reporting data from our Phase 1 trial in 1H 2021, initiating a randomized Phase 2 study in 1H 2021 while evaluating additional opportunities for SBP-101. “These Q3 accomplishments lay the foundation to execute on near-term milestones. Simpson, PhD, MSN, CRNP President & Chief Executive Officer of Sun BioPharma. “During the third quarter we strengthened our leadership team, bolstered the balance sheet and broadened our potential investor audience by uplisting to Nasdaq,” said Jennifer K. The third quarter of 2020 was marked by meaningful corporate, financial and clinical progress.įast Track designation received for SBP-101 Management is hosting an earnings call today at 4:30 p.m. (Nasdaq: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic cancer, today provides a business update and reports financial results for the quarter ended September 30, 2020. 12, 2020 (GLOBE NEWSWIRE) - Sun BioPharma, Inc.
0 Comments
Leave a Reply. |